TuHURA Biosciences Inc
HURA
Company Profile
Business description
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Contact
10500 University Center Drive
Suite 110
TampaFL33612
USAT: +1 813 875-6600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.70 | 38.80 | -0.43% |
| CAC 40 | 8,436.24 | 43.63 | -0.51% |
| DAX 40 | 25,465.25 | 352.64 | -1.37% |
| Dow JONES (US) | 52,925.15 | 130.76 | -0.25% |
| FTSE 100 | 10,665.88 | 14.11 | 0.13% |
| HKSE | 23,496.89 | 119.43 | -0.51% |
| NASDAQ | 25,818.69 | 302.47 | -1.16% |
| Nikkei 225 | 68,256.96 | 1,480.73 | -2.12% |
| NZX 50 Index | 13,762.79 | 0.31 | -0.00% |
| S&P 500 | 7,503.85 | 33.58 | -0.45% |
| S&P/ASX 200 | 8,803.90 | 35.50 | -0.40% |
| SSE Composite Index | 3,990.24 | 51.00 | -1.26% |